Glycoengineered anti-CD20 IgG1 monoclonal antibody that depletes malignant B cells via ADCC and complement.
Glycoengineered anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, leading to B-cell depletion; low-fucose Fc enhances ADCC.
YES
DIRECT
Binds CD20 on B cells and triggers Fc-mediated ADCC (enhanced by low-fucose Fc) and complement-dependent cytotoxicity, leading to lysis/apoptosis of CD20+ cells.
HER2-targeted antibody-drug conjugate that binds HER2, is internalized, and releases an intracellular cytotoxic payload; the antibody component also inhibits HER2 signaling and mediates ADCC.
HER2-targeted ADC that binds HER2 and is internalized; a cleavable linker releases the MMAE payload, which inhibits tubulin polymerization causing G2/M arrest and apoptosis; the antibody component also blocks HER2 signaling and mediates ADCC.
YES
DIRECT
The ADC binds HER2, is internalized, and releases MMAE that inhibits tubulin polymerization causing G2/M arrest and apoptosis; the antibody Fc can also trigger ADCC against HER2-expressing cells.
An anti-HER2 IgG1 monoclonal antibody that binds domain II of HER2 and blocks HER2 dimerization, especially HER2/HER3.
Humanized IgG1 monoclonal antibody targeting HER2 domain II to block HER2 dimerization—particularly HER2/HER3—thereby inhibiting downstream ERBB signaling (PI3K/AKT, MAPK) and inducing growth arrest/apoptosis; Fc engagement can also trigger ADCC.
YES
DIRECT
IgG1 antibody binds HER2 and recruits FcγR-expressing effector cells (e.g., NK cells) to kill via ADCC; HER2 dimerization blockade also suppresses survival signaling, promoting apoptosis.
HER2-targeted antibody-drug conjugate that binds HER2, is internalized, and releases an intracellular cytotoxic payload; the antibody component also inhibits HER2 signaling and mediates ADCC.
HER2-targeted ADC that binds HER2 and is internalized; a cleavable linker releases the MMAE payload, which inhibits tubulin polymerization causing G2/M arrest and apoptosis; the antibody component also blocks HER2 signaling and mediates ADCC.
NO
INDIRECT
DP303c targets HER2 on tumor cells; after HER2-mediated internalization, a cleavable linker releases MMAE that binds beta-tubulin to inhibit microtubule polymerization, causing G2/M arrest and apoptosis. Beta-tubulin is not the antigen recognized for targeting.
HER2-targeted antibody-drug conjugate linking trastuzumab to the microtubule inhibitor DM1; after HER2 binding and internalization, DM1 disrupts microtubules while trastuzumab retains HER2 blockade and ADCC.
HER2-targeted antibody–drug conjugate linking trastuzumab to the microtubule inhibitor DM1 via a nonreducible linker. After HER2 binding and internalization, intracellular DM1 disrupts microtubule dynamics to inhibit cell division and induce apoptosis, while the trastuzumab component blocks HER2 signaling and mediates Fc-dependent ADCC.
YES
DIRECT
The ADC binds HER2 on target cells, is internalized, and releases DM1 intracellularly to inhibit microtubules, causing mitotic arrest and apoptosis; trastuzumab Fc can also mediate ADCC against HER2+ cells.